Filtered By:
Drug: Fortamet

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 9822 results found since Jan 2013.

Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study
DISCUSSION: Contrary to current evidence and recommendations, SGLT2i and GLP1-RA were less likely to be prescribed to patients with pre-existing CVD, HF, and/or CKD, revealing opportunities to improve prescribing for patients with diabetes at high-risk for worsening cardiorenal complications.PMID:35606699 | DOI:10.1186/s12875-022-01731-w
Source: Primary Care - May 23, 2022 Category: Primary Care Authors: Robin Hao Tyler Myroniuk Taylor McGuckin Donna Manca Denise Campbell-Scherer Darren Lau Roseanne O Yeung Source Type: research

Antidiabetic treatment and COVID-19 Outcomes: A population-based cohort study in primary health care in Catalonia during the first wave of the pandemic
CONCLUSIONS: Patients receiving metformin monotherapy in our study showed a lower risk of hospitalization and death in comparison to those treated with other frequent antidiabetic agents. We cannot distinguish if better outcomes are related with the antidiabetic therapy or with other factors, such as metabolic control or interventions applied during the hospital admission.PMID:36216752 | DOI:10.1016/j.pcd.2022.10.001
Source: Primary Care - October 10, 2022 Category: Primary Care Authors: Dan Ouchi Carles Vilaplana-Carnerero Vanessa de Dios Maria Giner-Soriano Rosa Morros Source Type: research

Adherence to antidiabetic treatment among patients managed in primary care centres in Spain: the INTENSE study
CONCLUSIONS: Adherence to NIADs observed in our study is far from optimal. HbA1c and ARMS-e items could be used as adherence indicators to encourage treatment changes to improve T2DM control.PMID:36335018 | DOI:10.1016/j.pcd.2022.10.004
Source: Primary Care - November 5, 2022 Category: Primary Care Authors: Bogdan Vlacho Flora L ópez Simarro Manel Mata-Cases Sonia Miravet Jos é Escribano-Serrano David Asensio Xavi Cortes Josep Franch-Nadal Source Type: research

A comparison study of metformin only therapy and metformin combined with Chinese medicine jianyutangkang therapy in patients with type 2 diabetes: A randomized placebo-controlled double-blind study.
Abstract The aim of this 26-week, double-blind, controlled clinical trial, was to compare the efficacy of monotherapy (metformin only) with combination therapy (Chinese medicine prescription JianYuTangKang [JYTK] plus metformin) on type 2 diabetes. All patients on metformin were randomized to receive authenticated JYTK (59 patients) or placebo JYTK (53 patients), 4.5g daily, for 26 weeks. Patients also received information regarding diet and exercise. Fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1C) level, and a lipid profile were measured before, during, and after the treatment. The results of the...
Source: Complementary Therapies in Medicine - February 1, 2016 Category: Complementary Medicine Authors: Hu Y, Zhou X, Liu P, Wang B, Duan DM, Guo DH Tags: Complement Ther Med Source Type: research

Oriental herbal medicine and moxibustion for polycystic ovary syndrome: A meta-analysis
Conclusion: According to current evidence, OHM combined with moxibustion might be beneficial for treating PCOS. Moreover, the treatment might improve the therapeutic effects of conventional WMs including clomiphene citrate, oral contraceptives, and/or metformin. However, the findings should be interpreted with caution, owing to poor methodological quality of the included studies. Further larger, high-quality, rigorous RCTs should be conducted in this regard.
Source: Medicine - October 1, 2018 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Impact of Chinese Herbal Medicine on Glucolipid Metabolic Outcomes in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
CONCLUSION: Compared with the placebo group, Chinese herbal medicine had positive effects on glucolipid metabolism in women with PCOS. Chinese herbal medicine had a positive effect on lipid metabolism when the control group was metformin, but no effect on glucose metabolism. These findings need to be verified in high-quality, large-sample, randomized controlled trials in the future.PMID:36212945 | PMC:PMC9546672 | DOI:10.1155/2022/3245663
Source: Evidence-based Complementary and Alternative Medicine - October 10, 2022 Category: Complementary Medicine Authors: Jie Li Ruqun Zheng Zixin Lin Fangyuan Hu Ying Lin Guomei Zeng Jieni Fang Yingyan Shen Huiyan Tan Mei Han Juan Li Source Type: research

How Metformin Acts in PCOS Pregnant Women: Insights in insulin secretion and peripheral action at each trimester of gestation.
CONCLUSIONSWomen with PCOS who enter pregnancy in a condition of severe hyperinsulinemia have development of GD earlier, independently of metformin treatment. The physiologic deterioration of insulin sensitivity is not affected by the drug and does not predict the timing and severity of the glycemic imbalance. Despite the high incidence of GD observed, the drug itself or the intensive monitoring probably accounted for the good neonatal outcome. PMID: 23315599 [PubMed - as supplied by publisher]
Source: Diabetes Care - January 11, 2013 Category: Endocrinology Authors: Romualdi D, De Cicco S, Gagliano D, Busacca M, Campagna G, Lanzone A, Guido M Tags: Diabetes Care Source Type: research

Improvement in Surrogate Endpoints by a Multidisciplinary Team in a Mobile Clinic Serving a Low-income, Immigrant Minority Population in South Florida.
Abstract Abstract:To determine effect on surrogate endpoints for cardiovascular disease (CVD), we performed a retrospective chart review of 114 patients seen by a multidisciplinary team that provided primary care services in a mobile clinic over 12 months. Eligible patients had outcomes available for at least six months. Mixed effect modeling examined variation in surrogate markers for CVD: blood pressure (BP), heart rate, and body mass index. Repeated measures ANOVA compared lipids, hemoglobin A1c, and medication use from baseline and throughout study. Most patients were female (75%), Haitian (76%...
Source: Journal of Health Care for the Poor and Underserved - February 13, 2013 Category: Global & Universal Authors: Singh-Franco D, Perez A, Wolowich WR Tags: J Health Care Poor Underserved Source Type: research

Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial.
CONCLUSIONSWeight gain in ACCORD was greater with intensive than with standard treatment and generally associated with reduction of A1C from elevated baseline values. Initiation of TZD and/or insulin therapy was the most important medication-related factor associated with weight gain. PMID: 23412077 [PubMed - as supplied by publisher]
Source: Diabetes Care - February 14, 2013 Category: Endocrinology Authors: Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC, the ACCORD Study Group Tags: Diabetes Care Source Type: research

Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes: The TODAY clinical trial.
CONCLUSIONS Dyslipidemia and chronic inflammation were common in youth with type 2 diabetes and worsened over time. Diabetes treatment, despite some treatment group differences in lipid and inflammatory marker change over time, is generally inadequate to control this worsening risk. PMID: 23704675 [PubMed - in process]
Source: Diabetes Care - May 29, 2013 Category: Endocrinology Authors: TODAY Study Group Tags: Diabetes Care Source Type: research

Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY.
CONCLUSIONS The beneficial change in insulin sensitivity and the resultant lower burden on β-cell function achieved in the first 6 months with metformin plus rosiglitazone appear to be responsible for its superior glycemic durability over metformin alone and metformin plus lifestyle. However, initial β-cell reserve and HbA1c at randomization are independent predictors of glycemic durability. Therefore, efforts to preserve β-cell function before significant loss occurs and to reduce HbA1c may be beneficial in the treatment of youth with type 2 diabetes. PMID: 23704674 [PubMed - in process]
Source: Diabetes Care - May 29, 2013 Category: Endocrinology Authors: TODAY Study Group Tags: Diabetes Care Source Type: research

Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial.
CONCLUSIONS Despite differential effects on measures of adiposity (with M+R resulting in the most and M+L in the least fat accumulation), group differences generally were small and unrelated to treatment effects in sustaining glycemic control. PMID: 23704673 [PubMed - in process]
Source: Diabetes Care - May 29, 2013 Category: Endocrinology Authors: TODAY Study Group Tags: Diabetes Care Source Type: research

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes: The TODAY clinical trial.
CONCLUSIONS Prevalence of hypertension and microalbuminuria increased over time among adolescents with type 2 diabetes regardless of diabetes treatment. The greatest risk for hypertension was male sex and higher BMI. The risk for microalbuminuria was more closely related to glycemic control. PMID: 23704672 [PubMed - in process]
Source: Diabetes Care - May 29, 2013 Category: Endocrinology Authors: TODAY Study Group Tags: Diabetes Care Source Type: research

Metformin and the incidence of cancer in patients with diabetes: a nested case-control study.
PMID: 23970729 [PubMed - in process]
Source: Diabetes Care - August 28, 2013 Category: Endocrinology Authors: Wang SY, Chuang CS, Muo CH, Tu ST, Lin MC, Sung FC, Kao CH Tags: Diabetes Care Source Type: research